Cantargia is a clinical-stage biotechnology company listed on the Nasdaq Stockholm main market. It is developing CAN04 and CAN10 against IL1RAP. CAN04 is in a Phase IIa clinical trial, CANFOUR, in solid tumours focused on NSCLC and PDAC. It is is preparing to file an IND and initiate a trial in the US next year.
Cantargia is developing antibodies against IL1RAP. In December 2019 it reported interim data from the ongoing three-arm Phase IIa study with CAN04 in combination with first-line chemotherapy in non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). Four out of seven evaluable PDAC patients achieved partial response and two out of three evaluable NSLC patients achieved an objective response (one complete and one partial). The results compare favourably to historical response rates to standalone chemotherapy regimens (23% in PDAC; 22–28% in first-line NSCLC). The FDA has also approved Cantargia’s IND application for a Phase Ib trial in the US with CAN04 in combination with a CPI. CAN10 is a preclinical project in inflammation uniquely targeting three interleukins, IL-1, IL-33 and IL-36. In February 2020, Cantargia raised SEK410m, an impressive amount of capital for a pure-play European biotech.
Increasing the understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.